Medicine and Dentistry
Multiple Sclerosis
75%
Severe Acute Respiratory Syndrome Coronavirus 2
75%
Messenger RNA
65%
Cellular Immunity
50%
CD20
50%
Infection
50%
Ocrelizumab
45%
mRNA Vaccine
25%
Disease Course
25%
Humoral Immunity
25%
Cohort Analysis
25%
COVID-19 Vaccination
16%
Cytotoxic T-Cell
12%
Receptor Binding
12%
B Lymphocyte
8%
T Lymphocyte
8%
T-Cell Response
8%
Monoclonal Antibody
8%
B Cell
8%
Immunoglobulin G
8%
CD8+ T Lymphocyte
5%
Prophylaxis
5%
Observational Study
5%
Rituximab
5%
Diagnosis of Multiple Sclerosis
5%
Immunology and Microbiology
Multiple Sclerosis
100%
Severe Acute Respiratory Syndrome Coronavirus 2
75%
Ocrelizumab
68%
Adoptive Immunity
50%
CD20
50%
Breakthrough Infection
37%
Spike
29%
Humoral Immunity
25%
B Cell
20%
Immunology
18%
CD4
16%
T Cell
16%
Binding Antibody
12%
Receptor Binding
12%
Cytotoxic T-Cell
10%
Blood Level
8%
Immunoglobulin G
8%
Rituximab
6%
Diagnosis of Multiple Sclerosis
6%
Monoclonal Antibody
6%
Seropositivity
6%
Pharmacology, Toxicology and Pharmaceutical Science
SARS Coronavirus
50%
Multiple Sclerosis
50%
Messenger RNA
50%
Immunoglobulin G
16%
COVID-19 Vaccine
8%
Ocrelizumab
6%
CD8 Antigen
6%
Monoclonal Antibody
6%
